|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was evidence to support the use of FDG PET/MRI in staging of nasopharyngeal cancer and high-risk BC.
|
31267161 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the prognostic performance of radiomics features, as extracted from positron emission tomography (PET) and X-ray computed tomography (CT) components of baseline 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) PET/CT images and integrated with clinical parameters, in patients with nasopharyngeal carcinoma (NPC).
|
30671740 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eighty-two patients with NPC underwent F-FDG PET/CT prior to intensity-modulated radiation therapy (IMRT).
|
31305420 |
2019 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymph Node With the Highest FDG Uptake Predicts Distant Metastasis-Free Survival in Patients With Locally Advanced Nasopharyngeal Carcinoma.
|
29762247 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the impact of parameter settings as used for the generation of radiomics features on their robustness and disease differentiation (nasopharyngeal carcinoma (NPC) versus chronic nasopharyngitis (CN) in FDG PET/CT imaging).
|
29520429 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical utility of simultaneous whole-body <sup>18</sup>F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma.
|
29502310 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In consideration of the high target-to-background contrast, SSR ligands might be superior to F-FDG for EBV-associated NPC PET imaging, particularly at the skull base.
|
29401153 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whole-body <sup>18</sup>F-FDG PET/CT for M staging in the patient with newly diagnosed nasopharyngeal carcinoma: Who needs?
|
28267540 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from prospective and retrospective observational studies that used F-FDG PET to predict disease prognosis in NPC patients were used for analysis.
|
28445287 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 2685 patients with NPC who received bone scintigraphy (BS) and/or 18F-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and 2496 patients without skeletal metastasis were retrospectively assessed to develop individual nomograms for SMAD and SMFS.
|
28874126 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aim to evaluate the quantitative parameters of <sup>18</sup>F-FDG PET/CT (metabolic parameters) and MRI (morphologic parameters) for prognostication and risk stratification in nasopharyngeal carcinoma (NPC).
|
28871162 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FLT and <sup>18</sup>F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results.
|
28091565 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET/CT-positive CLNs could reasonably be categorized as high-risk clinical tumor volume in IMRT planning for NPC.
|
29187888 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>FDG PET/PET-CT is superior to BS for diagnosing bone metastases in nasopharyngeal cancer patients.<sup>18</sup>FDG PET/PET-CT may enhance the diagnosis of bone metastases and provide more accurate information for the optimal management of nasopharyngeal cancer.
|
28938677 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 47-year-old man with newly diagnosed nasopharyngeal carcinoma underwent staging F-FDG PET/CT.
|
28632691 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Advances in knowledge: We found that pre-treatment <sup>18</sup>F-FDG PET parameters of primary tumours and regional LNs (the SUV<sub>max</sub> and SUV<sub>peak</sub> of the primary tumour and the farthest LN station) were significant prognostic factors for DMFS in patients with nasopharyngeal carcinoma with LN involvement.
|
28008776 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An 18F-FDG-PET/CT scan and biopsy showed metastatic abdominal lymph nodes of nasopharyngeal carcinoma in April 2015.
|
29137018 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A systematic literature search was performed to identify studies which associated 18F-FDG PET/CT to clinical survival outcomes of nasopharyngeal carcinoma patients.
|
27980228 |
2017 |